Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment

2 months ago 35

Candel Therapeutics, Inc. (CADL) has disclosed a new risk, in the Innovation / R&D category. Candel Therapeutics, Inc. faces a significant business risk despite rec...

1. Homepage
2. Prostate Cancer
3. Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment